Načítá se...

Recombinant Enzyme Therapy for Fabry Disease: Absence of Editing of Human α-Galactosidase A mRNA

For more than a decade, protein-replacement therapy has been employed successfully for the treatment of Gaucher disease. Recently, a comparable therapy has become available for the related lipid-storage disorder Fabry disease. Two differently produced recombinant α-galactosidase A (α-gal A) preparat...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Blom, Daniël, Speijer, Dave, Linthorst, Gabor E., Donker-Koopman, Wilma G., Strijland, Anneke, Aerts, Johannes M. F. G.
Médium: Artigo
Jazyk:Inglês
Vydáno: The American Society of Human Genetics 2003
Témata:
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC420010/
https://ncbi.nlm.nih.gov/pubmed/12471562
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!